The combination of the noradrenergic agent reboxetine plus the anti-muscarinic hyoscine butylbromide reduces OSA severity, according to Australian researchers. Their preliminary study, published in the Journal of Physiology, provides the promise of a pharmacological approach to OSA – an alternative for patients struggling with adherence to CPAP. They investigated the repurposing of the drugs in ...
Repurposing old drugs to replace CPAP in sleep apnoea?
By Mardi Chapman
8 Jul 2021